X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Strides Arcolab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES SHASUN LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES SHASUN LTD AUROBINDO PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 14.3 13.0 109.7% View Chart
P/BV x 3.7 1.5 243.0% View Chart
Dividend Yield % 0.4 0.7 64.9%  

Financials

 AUROBINDO PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
STRIDES SHASUN LTD
Mar-17
AUROBINDO PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs8951,275 70.2%   
Low Rs622918 67.8%   
Sales per share (Unadj.) Rs254.6389.6 65.4%  
Earnings per share (Unadj.) Rs39.328.0 140.4%  
Cash flow per share (Unadj.) Rs46.648.9 95.3%  
Dividends per share (Unadj.) Rs2.504.50 55.6%  
Dividend yield (eoy) %0.30.4 80.3%  
Book value per share (Unadj.) Rs160.0303.1 52.8%  
Shares outstanding (eoy) m585.8889.42 655.2%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x3.02.8 105.9%   
Avg P/E ratio x19.339.2 49.3%  
P/CF ratio (eoy) x16.322.4 72.6%  
Price / Book Value ratio x4.73.6 131.1%  
Dividend payout %6.416.1 39.6%   
Avg Mkt Cap Rs m444,39098,036 453.3%   
No. of employees `00014.05.8 241.1%   
Total wages/salary Rs m17,6785,881 300.6%   
Avg. sales/employee Rs Th10,667.86,005.9 177.6%   
Avg. wages/employee Rs Th1,264.31,014.0 124.7%   
Avg. net profit/employee Rs Th1,645.8431.2 381.7%   
INCOME DATA
Net Sales Rs m149,15734,834 428.2%  
Other income Rs m1,1591,686 68.7%   
Total revenues Rs m150,31636,520 411.6%   
Gross profit Rs m34,3436,428 534.3%  
Depreciation Rs m4,2761,872 228.5%   
Interest Rs m6672,269 29.4%   
Profit before tax Rs m30,5583,973 769.1%   
Minority Interest Rs m500-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m7,597470 1,616.3%   
Profit after tax Rs m23,0122,501 920.1%  
Gross profit margin %23.018.5 124.8%  
Effective tax rate %24.911.8 210.1%   
Net profit margin %15.47.2 214.9%  
BALANCE SHEET DATA
Current assets Rs m92,06238,165 241.2%   
Current liabilities Rs m66,22330,402 217.8%   
Net working cap to sales %17.322.3 77.7%  
Current ratio x1.41.3 110.7%  
Inventory Days Days10677 137.0%  
Debtors Days Days68104 64.8%  
Net fixed assets Rs m62,91937,639 167.2%   
Share capital Rs m586894 65.5%   
"Free" reserves Rs m93,13326,210 355.3%   
Net worth Rs m93,71927,105 345.8%   
Long term debt Rs m1,81416,377 11.1%   
Total assets Rs m162,49481,168 200.2%  
Interest coverage x46.82.8 1,701.4%   
Debt to equity ratio x00.6 3.2%  
Sales to assets ratio x0.90.4 213.9%   
Return on assets %14.65.9 248.0%  
Return on equity %24.69.2 266.1%  
Return on capital %32.712.1 271.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83813,465 563.2%   
Fx outflow Rs m30,2244,076 741.6%   
Net fx Rs m45,6139,389 485.8%   
CASH FLOW
From Operations Rs m32,7862,881 1,137.8%  
From Investments Rs m-17,870-7,051 253.4%  
From Financial Activity Rs m-19,1533,382 -566.3%  
Net Cashflow Rs m-4,239-788 538.2%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   VENUS REMEDIES  MERCK LTD  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 22, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS